TScan Therapeutics (TCRX) Non-Current Deffered Revenue (2020 - 2025)
Historic Non-Current Deffered Revenue for TScan Therapeutics (TCRX) over the last 5 years, with Q1 2025 value amounting to $501000.0.
- TScan Therapeutics' Non-Current Deffered Revenue fell 8947.04% to $501000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $501000.0, marking a year-over-year decrease of 8947.04%. This contributed to the annual value of $1.2 million for FY2024, which is 7783.71% down from last year.
- TScan Therapeutics' Non-Current Deffered Revenue amounted to $501000.0 in Q1 2025, which was down 8947.04% from $1.2 million recorded in Q4 2024.
- Over the past 5 years, TScan Therapeutics' Non-Current Deffered Revenue peaked at $7.8 million during Q3 2023, and registered a low of $501000.0 during Q1 2025.
- Its 4-year average for Non-Current Deffered Revenue is $4.0 million, with a median of $4.0 million in 2024.
- In the last 5 years, TScan Therapeutics' Non-Current Deffered Revenue tumbled by 4826.01% in 2024 and then crashed by 8947.04% in 2025.
- Quarter analysis of 4 years shows TScan Therapeutics' Non-Current Deffered Revenue stood at $1.5 million in 2021, then skyrocketed by 275.55% to $5.6 million in 2023, then tumbled by 77.84% to $1.2 million in 2024, then plummeted by 59.79% to $501000.0 in 2025.
- Its Non-Current Deffered Revenue stands at $501000.0 for Q1 2025, versus $1.2 million for Q4 2024 and $3.7 million for Q3 2024.